Novo Nordisk, Eli Lilly Tumble After Study Suggests Weight-Loss Drugs Can Lead To Blindness
Novo Nordisk stock skidded Wednesday after a new study suggests its diabetes and weight-loss drug can lead to a blindness-causing disease.
Investor's Business Daily